Combined average of Moat (AI Resilience), Growth, and Valuation scores.
Moat Score
DTC telehealth subscription brand with vertical pharmacy and multi-category bundle — narrow brand moat. March 2026 Novo Nordisk branded GLP-1 partnership resolved the compounding lawsuit overhang but compressed weight-loss unit economics; July 2026 FTC privacy/billing suit re-opens regulatory tail risk.
Hims's moat is brand recognition + vertical pharmacy + multi-category subscription bundling in telehealth — real but narrow, with regulatory exposure now centred on FTC consumer-protection claims and branded-GLP-1 margin mix rather than compounded-semaglutide enforcement alone:
- DTC Brand Reach in Targeted Categories: Hims has built genuine brand awareness in men's hair loss, sexual health, mental health, weight-loss, and women's hormonal health. The marketing flywheel and CAC-LTV economics in established categories remain the franchise's core; Q1 subscribers reached 2.58M (+9% YoY) even as U.S. revenue dipped on the GLP-1 mix shift.
- Vertical Pharmacy and Branded GLP-1 Access: Hims operates its own compounding pharmacies, but the March 2026 Novo Nordisk collaboration put FDA-approved Ozempic and Wegovy (injectable and oral) on the platform at Novo self-pay prices and ended Novo's patent suit. Compounded GLP-1 is now limited to clinically necessary cases — a cleaner legal channel at structurally lower margin than 2024 compounded semaglutide.
- Clinical Network and International Scale: A national provider network plus ZAVA, Livewell, and the June 2026 Eucalyptus close (Australia/Canada/Germany/Japan/UK footprint; ~850K prior customers) extend the closed-loop subscription stack. Switching costs for the patient remain low; convenience-and-pricing UX vs traditional care is the retention lever.
Moat Verdict
Hims is a brand-and-bundle moat business in a regulated industry — AI is neutral-to-positive on cost (provider productivity) but the dominant moat questions are regulatory (now FTC + compounding history) and competitive. The Novo partnership cleans up GLP-1 legality at the cost of margin; the thesis remains execution-and-category-expansion, appropriately sized as speculative growth.
56.6 resilient · 43.1 vulnerable · 80/20 = 53.9 · = 54
Open a moat to read its note.
Subscription UX and re-fill workflow drive some switching cost, but rivals can replicate the UI quickly — and FTC cancellation allegations undercut any claim that retention is earned convenience alone.
Telehealth intake-to-prescription workflows are largely commoditised software.
N/A.
DTC marketing and telehealth-clinician supply are increasingly available at scale to competitors.
Multi-category subscription bundle (hair + weight + mental health + skin) creates real ARPU expansion and retention vs single-category telehealth — Hims's primary moat lever.
Subscription health-and-outcomes data across 2.6M+ patients is real, though monetisation is constrained by HIPAA/consent — and the July 2026 FTC suit over alleged sharing with Meta/Snap puts that data advantage under active regulatory scrutiny.
No regulatory moat — telehealth and compounding rules protect nobody's position. The April 2025 GLP-1 compounding ban and the July 2026 FTC privacy/billing complaint are structural regulatory risk, charged in the growth keyRisk rather than scored here as an eroded moat. Previously weakened.
DTC subscription, not a network-effects business.
Subscription auto-fills, integrated lab workups, and chronic-care titration plans create real friction for swap-out at the patient level.
Hims is becoming the system of record for personalised chronic-care for younger demographics, but the moat is shallow vs primary care + EHR systems.
Not a source of durability for this business: no structural unit-cost gap versus rivals that the other pillars do not already capture.
Hims & Hers is a recognised direct-to-consumer telehealth brand that acquires customers with less paid spend than new entrants, but FTC scrutiny and GLP-1 compounding history dent the trust the brand relies on.
Moat in 5–10 years
Hims's moats hold where they are. The multi-category subscription bundle and the brand carry the score, and the March 2026 Novo collaboration put branded GLP-1s on the platform rather than taking the category away. The FTC privacy and billing suit is a live risk to the data and brand pillars, but it is charged in the growth keyRisk until an outcome lands, so no pillar is called in either direction.
No moat trending · 54 holds
Combined average of Moat (AI Resilience), Growth, and Valuation scores.
Moat Score
DTC telehealth subscription brand with vertical pharmacy and multi-category bundle — narrow brand moat. March 2026 Novo Nordisk branded GLP-1 partnership resolved the compounding lawsuit overhang but compressed weight-loss unit economics; July 2026 FTC privacy/billing suit re-opens regulatory tail risk.
Growth Score
Q3 2026 (reported Nov 9, after the close): revenue $890.4M, +49% YoY (second straight acceleration), in line with consensus; U.S. +21% to ~$657M and Rest of World $233M (+321%, mostly Eucalyptus). Subscribers ~2.79M (+317k YoY); monthly revenue per subscriber $105 (+30%) on branded GLP-1 mix. Gross margin fell to 57% from 74%; adjusted EBITDA margin 9% (13%); GAAP net loss ~$33M including FTC legal accruals of ~$60M year to date. FY26 revenue guide tightened to $3.13–3.15B; adjusted EBITDA cut to $257–277M (8–9% margin). Hims signed a direct deal with Lilly (Nov 6) to offer Zepbound and Foundayo. Q3 FCF $26M; $1.4B of converts and a $563M Eucalyptus deferred payable outstanding. Q1 revenue $608M (+4% YoY) was a transition print after the branded-GLP-1 pivot; Q2 (reported Aug 10) was $753M (+38%) at a 64% gross margin, with the FY26 guide then at $3.1–3.3B and Adj EBITDA $275–325M. 2030 targets remain ≥$6.5B revenue / $1.3B Adj EBITDA.
Valuation Score
Re-marked at the $22.94 close on November 9, 2026, the day of the Q3 print: 88 on the unchanged $22 / $35 / $68 ladder, from 76 at the $29.30 mark. The stock fell about 12% on the day into the print and about 3% more after hours (~$22.20). The ladder is held; the bear case already assumes branded GLP-1 margins and legal costs cap earnings. At ~$29.30 (September 24, 2026) HIMS trades at ~2.3× FY26 sales on the ~$2.9B guide midpoint, a sharp de-rating from the ~4.5-5× / ~$50 regime in May. The base is trimmed from $42 (~3× sales) to $35 (~2.5× sales) so it sits within ~12% of the ~$31 Street mean target rather than ~34% above it. Spot sits ~33% above the $22 bear and ~16% below base; the multiple prices execution and FTC risk honestly but leaves limited cushion if H2 margins disappoint.
The DTC Telehealth Brand Moat
Hims's moat is brand recognition + vertical pharmacy + multi-category subscription bundling in telehealth — real but narrow, with regulatory exposure now centred on FTC consumer-protection claims and branded-GLP-1 margin mix rather than compounded-semaglutide enforcement alone:
- DTC Brand Reach in Targeted Categories: Hims has built genuine brand awareness in men's hair loss, sexual health, mental health, weight-loss, and women's hormonal health. The marketing flywheel and CAC-LTV economics in established categories remain the franchise's core; Q1 subscribers reached 2.58M (+9% YoY) even as U.S. revenue dipped on the GLP-1 mix shift.
- Vertical Pharmacy and Branded GLP-1 Access: Hims operates its own compounding pharmacies, but the March 2026 Novo Nordisk collaboration put FDA-approved Ozempic and Wegovy (injectable and oral) on the platform at Novo self-pay prices and ended Novo's patent suit. Compounded GLP-1 is now limited to clinically necessary cases — a cleaner legal channel at structurally lower margin than 2024 compounded semaglutide.
- Clinical Network and International Scale: A national provider network plus ZAVA, Livewell, and the June 2026 Eucalyptus close (Australia/Canada/Germany/Japan/UK footprint; ~850K prior customers) extend the closed-loop subscription stack. Switching costs for the patient remain low; convenience-and-pricing UX vs traditional care is the retention lever.
Moat Verdict
Hims is a brand-and-bundle moat business in a regulated industry — AI is neutral-to-positive on cost (provider productivity) but the dominant moat questions are regulatory (now FTC + compounding history) and competitive. The Novo partnership cleans up GLP-1 legality at the cost of margin; the thesis remains execution-and-category-expansion, appropriately sized as speculative growth.
56.6 resilient · 43.1 vulnerable · 80/20 = 53.9 · = 54
Open a moat to read its note.
Subscription UX and re-fill workflow drive some switching cost, but rivals can replicate the UI quickly — and FTC cancellation allegations undercut any claim that retention is earned convenience alone.
Telehealth intake-to-prescription workflows are largely commoditised software.
N/A.
DTC marketing and telehealth-clinician supply are increasingly available at scale to competitors.
Multi-category subscription bundle (hair + weight + mental health + skin) creates real ARPU expansion and retention vs single-category telehealth — Hims's primary moat lever.
Subscription health-and-outcomes data across 2.6M+ patients is real, though monetisation is constrained by HIPAA/consent — and the July 2026 FTC suit over alleged sharing with Meta/Snap puts that data advantage under active regulatory scrutiny.
No regulatory moat — telehealth and compounding rules protect nobody's position. The April 2025 GLP-1 compounding ban and the July 2026 FTC privacy/billing complaint are structural regulatory risk, charged in the growth keyRisk rather than scored here as an eroded moat. Previously weakened.
DTC subscription, not a network-effects business.
Subscription auto-fills, integrated lab workups, and chronic-care titration plans create real friction for swap-out at the patient level.
Hims is becoming the system of record for personalised chronic-care for younger demographics, but the moat is shallow vs primary care + EHR systems.
Not a source of durability for this business: no structural unit-cost gap versus rivals that the other pillars do not already capture.
Hims & Hers is a recognised direct-to-consumer telehealth brand that acquires customers with less paid spend than new entrants, but FTC scrutiny and GLP-1 compounding history dent the trust the brand relies on.
Moat in 5–10 years
Hims's moats hold where they are. The multi-category subscription bundle and the brand carry the score, and the March 2026 Novo collaboration put branded GLP-1s on the platform rather than taking the category away. The FTC privacy and billing suit is a live risk to the data and brand pillars, but it is charged in the growth keyRisk until an outcome lands, so no pillar is called in either direction.
No moat trending · 54 holds
Growth Analysis
Growth Drivers
Key Risk
If the July 2026 FTC/state privacy-and-billing suit forces a large settlement or advertising restrictions, or if gross margin keeps falling from Q3's 57% as the branded and international mix grows, FY26 EBITDA misses the $257-277M guide and the multiple re-rates toward 1.5× sales.
Score Derivation
86.0 base + 1.3 trajectory − 4 margin − 10 risk = 73
Base 86 (24% midpoint of 20-28%) +1.3 trajectory (international/category accelerating; weight-loss and subscribers stable through the branded pivot) −4 margin (gross margin 57% in Q3 vs 74% YoY; FY26 Adj EBITDA margin guided 8-9%) −10 high regulatory/FTC risk = 73. Down from ~81: the old 30-45% CAGR no longer answers to the guided or 2030 series after the compounded-to-branded GLP-1 reset.
Price Scenarios (12–24 Months)
Price vs Targets
Dashed lines mark the 12–24 month bear, base and bull targets. Daily closes.
Valuation Multiples
| Price / Sales (FY26) | ~2.5× |
| EV / Adj EBITDA (FY26) | ~25× |
| Forward P/E (FY26) | N/M |
| Street 12-mo PT | ~$31 |
| FCF (Q1) | $53M |
Valuation has reset with the stock; the equity remains a high-volatility execution-and-regulatory position. Base case assumes the FY26 guide holds and FTC overhang is manageable — not a quality-compounder multiple.
Approximate figures as of August 10, 2026.
Where We Are vs Targets
Loading live price…
FTC suit escalates costs/CAC, branded weight-loss margins stay compressed, FY26 EBITDA misses — multiple compresses toward ~1.5× sales.
- FTC/state action forces material settlement, ad restrictions, or cancellation-UX changes that lift CAC
- Branded Wegovy/Ozempic mix keeps gross margin near mid-60s without H2 operating leverage
- Subscriber growth stalls below ~10% YoY as weight-loss ARPU normalises
FY26 revenue delivered near guide midpoint, Q2 confirms re-acceleration, Adj EBITDA margin exits toward guide, multiple holds ~2.5× sales.
- Q4 prints inside the $875-895M revenue / $70-90M Adj EBITDA guide, landing FY26 at $3.13-3.15B / $257-277M
- Weight-loss settles into branded Novo mix with stabilising gross margin
- International (Eucalyptus + ZAVA/Livewell) and new categories reach a meaningful revenue share
Hims becomes the leading multi-country DTC chronic-care platform, 2030 path looks credible, Adj EBITDA margin expands toward mid-teens, multiple re-rates toward 4×+ sales.
- Subscriber base scales past 3.5M with improving NRR as diagnostics/personalisation land
- Eucalyptus integration lifts RoW without proportional margin dilution
- FTC resolved without franchise damage; category mix diversifies away from GLP-1 concentration
HIMS: common questions
Is Hims & Hers Health stock a buy?
We rate Hims & Hers Health Hold, with a composite score of 71/100: moat 54, growth 73 and valuation 88. The valuation score is struck against our bear, base and bull targets and moves with the price.
What is Hims & Hers Health's moat?
Hims & Hers Health scores 54/100 on moat. DTC telehealth subscription brand with vertical pharmacy and multi-category bundle — narrow brand moat.
How fast is Hims & Hers Health expected to grow?
We estimate 20-28% a year over the next three to five years, for a growth score of 73/100.
What is Hims & Hers Health's price target?
Our base case is $35, with $22 in the bear case and $68 in the bull case.